Richard Gawel on Muck Rack

Richard Gawel

Verified
New York
As seen in: Healio Allergy/Asthma, Wiley Online Library, Memory Studies, SAGE Publishing, Flipboard, EIN News, Endocrine Today, Healio, Healio Neurology, Healio Women’s Health & OB/GYN, HemOnc Today and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

US overdose deaths fall 24.4% from 2023 to 2024, but disparities persist

|
By Richard Gawel Verified
| Healio Verified
Key takeaways: Rates of deaths involving fentanyl with stimulants fell in 2024. Black and Native American communities had overdose death rates higher than the national average. Overdose deaths in the United States fell 24.4% from 2023 to 2024, primarily due to decreases in deaths due to illegal fentanyl, according to a study published in Addiction. But even though these declines were seen across all racial and ethnic groups, disparities persist, according to Joseph R.
Open in Who Shared Issue with article?

More than half of patients with tardive dyskinesia see symptom remission with valbenazine Original

|
By Richard Gawel Verified
| Healio Neurology Verified
Patients took 40 mg or 80 mg of daily valbenazine for 48 weeks. The Abnormal Involuntary Movement Scale was used to measure improvement. Movement severity began receding toward baseline after ending treatment. More than half of patients with tardive dyskinesia who used valbenazine experienced symptomatic remission at 48 weeks, and nearly all of them had meaningful response, according to data presented at Psych Congress Elevate in Las Vegas.
Open in Who Shared View Duplicates (2) Issue with article?

More than half of patients with tardive dyskinesia see symptom remission with valbenazine

|
By Richard Gawel Verified, Shenaz Bagha Verified, Dawn Vanderhoef
| Citeline Verified
Key takeaways: Patients took 40 mg or 80 mg of daily valbenazine for 48 weeks. The Abnormal Involuntary Movement Scale was used to measure improvement. Movement severity began receding toward baseline after ending treatment. More than half of patients with tardive dyskinesia who used valbenazine experienced symptomatic remission at 48 weeks, and nearly all of them had meaningful response, according to data presented at Psych Congress Elevate in Las Vegas.
Open in Who Shared Issue with article?
See all 1,854 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified